Thus, although our results did not reach statistical significance, probably due to the small number of samples, we confirmed the progressive downregulation of miR132-3p in AD samples grouped into Initial-Intermediate-Late but not significantly different in adult mouse brains with a different dosage of PrPC expression, which would explain how additional splicing factors (for instance miR132-3p) reduce the effects of PrPC-GSK3β in the prevalence of 3R and 4R tau isoforms in AD. This evidence concerns the gene MAPT and Alzheimer disease.